3001513
print

CYP2D6

2D6GENO
Example Reports
Intermediate Phenotype
Negative
Normal Phenotype
Poor Phenotype
Ultra Rapid Phenotype

Icon

Informed Consent for Genetic Testing (required for NY patients)

Ordering Recommendation

Assesses genetic risk of abnormal drug metabolism for CYP2D6 substrates. May aid in drug selection and dose planning for drugs metabolized by CYP2D6.

Methodology

Polymerase Chain Reaction/Fluorescence Monitoring/Sequencing

Performed

Varies

Reported

5-10 days
If reflexed: 5-7 additional days are required for LR-PCR and sequencing

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month

Reference Interval

By report

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is inteded for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are avialable online.

Compliance Category

Laboratory Developed Test (LDT)

Note

Whole blood is the preferred specimen type. Saliva samples that yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-determined criteria for reporting. Saliva is only validated for the OpenArray and CNV portions of testing and not the long-range PCR/duplication testing. Long-range PCR/duplication testing will not be performed for saliva samples.

If long-range PCR/duplication testing is performed, additional charges will apply. Approximately less than 5% of samples require 2D6 copy number determination.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
11/14/2022
X
X
08/15/2022
X
X
X
02/22/2022
X
X
X
N/A

CPT Codes

81226; if reflexed, add 81479

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
2008926 CYP2D6 Phenotype 79715-9
3001514 2D6GENO Specimen 31208-2
3001515 CYP2D6 Genotype 40425-1
3001516 2D6GENO Interpretation 50398-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • 2D6
  • amitriptyline
  • antidepressants
  • antipsychotics
  • aripiprazole
  • atomoxetine
  • clomipramine
  • codeine
  • CYP2D6
  • Cytochrome P450 2D6
  • desipramine
  • doxepine
  • flecainide
  • fluvoxamine
  • haloperidol
  • hydrocodone
  • imipramine
  • metoprolol
  • mitrazapine
  • nortriptyline
  • ondansetron
  • opioids
  • oxycodone
  • paroxetine
  • propafenone
  • risperidone
  • SSRIs
  • tamoxifen
  • TCAs
  • tramadol
  • trimipramine
  • tropisetron
  • venlafaxine
  • zuclopenthixol
CYP2D6